Financial insights of BSX

MyFinsight

For the quarter ending 2026-03-31, BSX made $5,203M in revenue. $1,341M in net income. Net profit margin of 25.77%.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Net sales	5,203	5,285	5,065	5,061
Cost of products sold (excluding amortization expense)	1,590	1,608	1,523	1,637
Gross profit	3,614	3,678	3,542	3,424
Selling, general and administrative expenses	1,781	1,833	1,741	1,716
Research and development expenses	516	569	514	526
Royalty expense	12	6	12	14
Amortization expense	232	228	225	225
Intangible asset impairment charges	-	-23*	0	46
Contingent consideration net expense (benefit)	-30	7	11	-5
Restructuring net charges (credits)	3	16	-8	83
Litigation-related net charges (credits)	-	218*	-	-
Operating expenses	2,513	2,854	2,494	2,605
Operating income (loss)	1,101	825	1,048	819
Interest expense	90	90	87	90
Other, net	151	-35	-23	213
Income (loss)before income taxes	1,162	700	939	941
Income tax expense (benefit)	-176	31	183	146
Net income (loss)	1,339	670	755	795
Preferred stock dividends	-	0	-	-
Net income (loss) attributable to noncontrolling interests	-2	-2	0	-2
Net income (loss) attributable to boston scientific common stockholders	1,341	672	755	797

Basic EPS	0.9	0.453	0.51	0.54
Diluted EPS	0.9	0.449	0.51	0.53
Basic Average Shares	1,484,900,000	1,482,800,000	1,481,700,000	1,479,900,000
Diluted Average Shares	1,495,000,000	1,495,900,000	1,495,500,000	1,493,500,000

Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.